EPTQ (Epitique) Dermal Filler Line — JETEMA ZEEP™ Technology — 1.1ml
- JETEMA ZEEP™ Technology — 24 mg/mL HA + 0.3% lido
- Three depth-tuned SKUs: S100, S300, S500
- CE 2292 certified, KFDA approved
- For licensed professionals only
| 1 – 2 boxes | $37.50 / box |
| 3 – 9 boxes | $35.63 / box |
| 10 – 19 boxes | $33.75 / box |
| 20 – 29 boxes | $32.63 / box |
| 30+ boxes | Contact for quote |
What Is EPTQ (Epitique) Dermal Filler Line — JETEMA ZEEP™ Technology — 1.1ml?
**EPTQ (Epitique)** is a three-variant Korean HA dermal filler series manufactured by JETEMA Co., Ltd., utilizing ZEEP™ purification technology to deliver 24 mg/mL cross-linked hyaluronic acid with 0.3% lidocaine in three depth-tuned formulations (S100, S300, S500) spanning superficial dermis to deep subcutaneous correction for licensed professionals.
EPTQ (Epitique) shares JETEMA's ZEEP™ purification platform with Starfill, targeting ultra-low endotoxin levels (<0.1 EU/mL) and a modification degree (MoD) of approximately 1% for minimized residual BDDE. Three variants — S100, S300, and S500 — are differentiated by cross-linking density rather than HA concentration, offering precise depth matching from superficial dermal correction to deep subcutaneous volumization with results lasting up to 12 months.
Specifications
| Product name | EPTQ (Epitique) Dermal Filler Line — ZEEP™ Technology |
|---|---|
| Active ingredient | Cross-linked HA 24 mg/mL + Lidocaine 0.3% |
| Volume | 1 × 1.1ml pre-filled syringe + 2 × 27G needles |
| Modification degree | ~1% (MoD) |
| Cross-linker | BDDE (ZEEP process) |
| Application | Intradermal to subcutaneous per variant |
| Treatment areas | Fine lines, periorbital, neck, NLF, marionettes, lips, cheeks, chin, jawline, nose |
| Origin | South Korea (JETEMA Co., Ltd.) |
| Certification | CE 2292, KFDA, ISO 13485 |
| Storage | 2–25°C, do not freeze, protect from light |
| Shelf life | 24 months unopened |
Key Benefits
- ZEEP™ purification delivers ultra-low endotoxin (<0.1 EU/mL) with ~1% modification degree for minimized BDDE residue
- Three cross-linking densities (S100/S300/S500) match every dermal depth from superficial lines to subcutaneous volumization
- 24 mg/mL HA concentration with consistent backbone across all variants ensures predictable clinical outcomes
- CE 2292 and KFDA certified for regulatory confidence in professional practice
- Room-temperature stable storage (2–25°C) eliminates cold-chain logistics
Suggested Treatment Protocol
Treatment protocol varies by variant. EPTQ S100 is injected into the superficial-to-mid dermis for fine lines and periorbital area. EPTQ S300 targets the mid-to-deep dermis using a 27G needle for nasolabial folds, marionette lines, and lip body augmentation. EPTQ S500 is placed in the subcutaneous plane for cheek augmentation, chin projection, jawline contouring, and nose dorsum support. A full treatment plan of 1–3 sessions with 4–8 week intervals is recommended. The exact injection depth, volume, and treatment schedule should be determined by the treating practitioner based on individual patient anatomy and aesthetic goals.
Quality product that delivers as expected.
The 1.1ml syringe format is convenient for our clinic workflow. Less waste compared to the 1.5ml syringes we used to buy.
Decent product for the price point. Does what it's supposed to do.
Good value for the price. Our clinic has been satisfied with the results so far.
Please log in to leave a review.